Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
injections <strong>of</strong> botulinum toxin in the treatment <strong>of</strong> blepharospasm and hemifacial spasm. J Neurol<br />
249: 64-68<br />
29. Calabrese P (2006) Neuropsychology <strong>of</strong> multiple sclerosis. An overview. J Neurol 253: 10–15.<br />
30. Calcagno P, Ruoppolo G, Grasso MG, De Vincentiis M, Paolucci S (2002) Dysphagia in multiple<br />
sclerosis - prevalence and prognostic factors. Acta Neurol Scand 105:40-43<br />
31. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W, Strosser W,<br />
Ballering-Bruhl B, Schafer M (2000) Efficacy <strong>of</strong> trospium chloride in patients with detrusor instability:<br />
a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85:659-<br />
664<br />
32. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM (2004)<br />
Randomized, double-blind placebo controlled trial <strong>of</strong> the once daily antimuscarinic agent Solifenacin<br />
succinate in patients with overactive bladder. J Urol. 172:1919-1924<br />
33. Castello T, Girona L, Gomez MR, Mena Mur A, Garcia L (1996) The possible value <strong>of</strong> ascorbic acid as a<br />
prophylactic agent for urinary tract infection. Spinal Cord 34:592-593<br />
34. Chancellor MB, Appell RA, Sathyan G, Gupta SK (2001) A comparison <strong>of</strong> the effects on saliva<br />
output <strong>of</strong> oxybutynin chloride and tolterodine tartrate. Clin Ther 23:753-760<br />
35. Chapple C (2004a) Darifenacin is effective in improving the major symptoms <strong>of</strong> overactive bladder: A<br />
pooled analysis <strong>of</strong> phase III studies. Eur Urol Suppl 3:A512<br />
36. Chapple CR, Rechberger T, Al-Shukri S, and the YM-905 Study Group (2004b) Randomized, double-blind<br />
placebo- and tolterodine-controlled trial <strong>of</strong> the once-daily antimuscarinic agent Solifenacin in patients<br />
with symptomatic overactive bladder. BJU Int. 93:303-310.<br />
37. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P (2000) Long-term<br />
results <strong>of</strong> sacral nerve stimulation (S3) for the treatment <strong>of</strong> neurogenic refractory urge incontinence<br />
related to detrusor hyperreflexia. J Urol 164:1476-1480<br />
38. Cheng JS, Sanchez-Mejia RO, Limbo M, Ward MM, Barbaro NM (2005) Management <strong>of</strong> medically<br />
refractory trigeminal neuralgia in patients with multiple sclerosis. Neurosurg Focus 18<br />
(www.medscape.com/viewarticle/505388 )<br />
39. Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH.(2005) Treating learning impairments improves<br />
memory performance in multiple sclerosis: a randomized clinical trial.<br />
Mult Scler 11:58-68<br />
40. Chiu MJ, Chang YC, Hsiao TY (2004) Prolonged effect <strong>of</strong> botulinum toxin injection in the treatment<br />
<strong>of</strong> cricopharyngeal dysphagia: case report and literature review. Dysphagia 19:52-57<br />
41. Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB (2006) Effects <strong>of</strong><br />
donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006; 245: 127–136<br />
42. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH (2002) Depressive symptoms<br />
and severity <strong>of</strong> illness in multiple sclerosis: epidemiologic study <strong>of</strong> a large community sample. Am<br />
43 E<strong>MS</strong>P, <strong>Symptomatic</strong> <strong>Treatment</strong> <strong>of</strong> <strong>Multiple</strong> <strong>Sclerosis</strong>, December 2006 - revised in April 2008
Change language